A window‐of‐opportunity biomarker study of etodolac in resectable breast cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 2045-7634|2045-7634|10|1583-1588

ISSN： 2045-7634

Source： Cancer Medicine, Vol.2045-7634, Iss.10, 2015-10, pp. : 1583-1588

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial

By Hadad Sirwan  

Breast Cancer Research and Treatment, Vol. 128, Iss. 3, 2011-08 ,pp. : 783-794

Springer Publishing Company

Access to resources Recommend Favorite

Window of opportunity: A new insight into sequential bevacizumab and paclitaxel in two cases of metastatic triplenegative breast cancer

By      

Experimental and Therapeutic Medicine, Vol. 10, Iss. 3, 2015-01 ,pp. : 885-888

Spandidos Publications

Access to resources Recommend Favorite

DNA methylation as a biomarker in breast cancer

By Martens John WM   Margossian Astrid L   Schmitt Manfred   Foekens John   Harbeck Nadia  

Future Oncology, Vol. 5, Iss. 8, 2009-10 ,pp. : 1245-1256

Future Medicine

Access to resources Recommend Favorite

Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation

By Fabi Alessandra  

Cancer Chemotherapy and Pharmacology, Vol. 62, Iss. 4, 2008-09 ,pp. : 717-725

Springer Publishing Company

Access to resources Recommend Favorite

A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer

By Higgins Michaela  

Breast Cancer Research and Treatment, Vol. 131, Iss. 3, 2012-02 ,pp. : 915-924

Springer Publishing Company

Access to resources Recommend Favorite